Nutriband (NTRB) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Nutriband (NTRB) over the past year, gaining 2.0% versus a loss of 28.8%. Over five years, NTRB leads with a -11.2% price change compared with -91.7% for PDSB. PDS Biotechnology is the larger company by market cap ($73.9 million vs $73.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTRB | PDSB |
|---|---|---|
| Share price | $6.05 | $1.02 |
| Market cap | $73.54M | $73.92M |
| 1-day change | -10.44% | -4.23% |
| YTD return | +33.26% | +32.47% |
| 1-year return | -28.82% | +2.00% |
| 5-year return | -11.15% | -91.73% |
| EPS (TTM) | $-0.53 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.19 | $1.55 |
| 52-week low | $2.80 | $0.195 |
| Distance from 52-week high | -34.13% | -34.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +147.93% | +390.20% |
| Average volume | 62.42K | 23.24M |
| Shares outstanding | 12.16M | 72.47M |
| Employees | — | 21 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed NTRB by 30.8 percentage points over the past year.
About Nutriband
NTRB stock →Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.
Health Care · Industrial Specialties
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
NTRB vs PDSB FAQ
Which is bigger, Nutriband or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $73.92M compared with $73.54M for Nutriband (NTRB).
Which stock has performed better over the past year, NTRB or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -28.82% for NTRB (price return, excluding dividends). Past performance does not predict future results.
Are Nutriband and PDS Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Nutriband and Biotechnology: Pharmaceutical Preparations for PDS Biotechnology.